Detalles de la búsqueda
1.
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.
Oncologist
; 29(3): e372-e381, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796838
2.
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
Cancer Immunol Immunother
; 72(7): 2127-2135, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828963
3.
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Lancet Oncol
; 23(7): 865-875, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35660139
4.
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study.
Oncologist
; 27(9): e723-e730, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815922
5.
Cancer patient perspective in the arena of COVID-19 pandemic.
Psychooncology
; 31(1): 39-45, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34315188
6.
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study.
Graefes Arch Clin Exp Ophthalmol
; 260(5): 1535-1542, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35067771
7.
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Curr Treat Options Oncol
; 22(8): 69, 2021 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34110510
8.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
9.
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cancer Treat Rev
; 123: 102669, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141462
10.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Clin Lung Cancer
; 25(2): 190-195, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262770
11.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042716
12.
Management of lung cancer patients during COVID-19 pandemic: dos, don'ts and don't knows.
Explor Target Antitumor Ther
; 3(3): 321-336, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045909
13.
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition.
Lung Cancer
; 165: 91-101, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114509
14.
Non-small-cell lung cancer: how to manage EGFR-mutated disease.
Drugs Context
; 112022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35975029
15.
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.
Cancers (Basel)
; 14(19)2022 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230686
16.
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Drugs Context
; 112022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36452878
17.
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Eur J Cancer
; 172: 357-366, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35834843
18.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease.
Drugs Context
; 112022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35975031
19.
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study.
Breast
; 65: 164-171, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998429
20.
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Thorac Cancer
; 13(3): 483-488, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34939342